{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:53:36Z","timestamp":1778010816536,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08793"],"award-info":[{"award-number":["22K08793"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02778"],"award-info":[{"award-number":["21H02778"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aims to evaluate both the short- and long-term outcomes of preoperative chemoradiotherapy (CRT) using the tegafur-uracil\/calcium folinate\/irinotecan (TEGAFIRI) regimen in patients with locally advanced rectal cancer (LARC). While total neoadjuvant therapy (TNT) is becoming more common, CRT may still be the optimal approach in certain cases to improve prognosis and reduce adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-center, retrospective cohort study included patients with histologically confirmed nonmetastatic primary adenocarcinoma of the lower rectum treated with preoperative CRT using the TEGAFIRI regimen (TEGAFIRI group). The control group comprised patients treated with tegafur-uracil\/calcium folinate (UFT group). The primary endpoint was the pathologic complete response (pCR) rate. Secondary endpoints included adverse events, overall survival (OS), disease-free survival (DFS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS). The background was adjusted using inverse probability weighting (IPW) calculated with the propensity score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The TEGAFIRI group consisted of 79 patients, while the UFT group included 264. The standardized pCR rates through the IPW were as follows: TEGAFIRI group: 24.3%, UFT group: 8.8%, and the difference in pCR was 15.4% (<jats:italic>P<\/jats:italic>\u2009=\u20090.01). Adverse events of grade 3 or higher were observed in 15.2% vs. 8.7% (adjusted) (13.6% vs. 9.1% crude) in the TEGAFIRI group and the UFT group. The standardized LRFS was significantly higher in the TEGAFIRI group (HR\u2009=\u20090.39, (95% CI 0.16\u20130.98), <jats:italic>P<\/jats:italic>\u2009=\u20090.045). There were no significant differences in OS, DFS, or DRFS between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The TEGAFIRI regimen for preoperative CRT in LARC demonstrated a high pCR rate and reduced local recurrence, with manageable adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00384-025-04867-0","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:42:09Z","timestamp":1743280929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Shigenobu","family":"Emoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Murono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"17","key":"4867_CR1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731\u20131740","journal-title":"N Engl J Med"},{"issue":"7","key":"4867_CR2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679\u2013687","journal-title":"Lancet Oncol"},{"issue":"5","key":"4867_CR3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702\u2013715","journal-title":"Lancet Oncol"},{"issue":"1","key":"4867_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29\u201342","journal-title":"Lancet Oncol"},{"issue":"15","key":"4867_CR5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C et al (2022) Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 40(15):1681\u20131692","journal-title":"J Clin Oncol"},{"issue":"5","key":"4867_CR6","first-page":"500","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H et al (2024) Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Orthod 42(5):500\u2013506","journal-title":"J Clin Orthod"},{"issue":"4","key":"4867_CR7","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 278(4):e766\u2013e772","journal-title":"Ann Surg"},{"issue":"9","key":"4867_CR8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamaoncol.2020.2394","volume":"6","author":"M Diefenhardt","year":"2020","unstructured":"Diefenhardt M, Ludmir EB, Hofheinz RD et al (2020) Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial: a post hoc analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial. JAMA Oncol 6(9):1416\u20131421","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"4867_CR9","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1200\/JCO.2020.38.15_suppl.4101","volume":"38","author":"D Sebag-Montefiore","year":"2020","unstructured":"Sebag-Montefiore D, Adams R, Gollins S et al (2020) ARISTOTLE: a phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC). J Clin Oncol. 38(15_suppl):4101\u20134101","journal-title":"J Clin Oncol."},{"issue":"36","key":"4867_CR10","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1200\/JCO.20.01932","volume":"38","author":"J Zhu","year":"2020","unstructured":"Zhu J, Liu A, Sun X et al (2020) Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer. J Clin Oncol 38(36):4231\u20134239","journal-title":"J Clin Oncol"},{"issue":"3","key":"4867_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clcc.2018.05.010","volume":"17","author":"K Kawai","year":"2018","unstructured":"Kawai K, Sunami E, Hata K et al (2018) Phase I\/II study of preoperative chemoradiotherapy with TEGAFIRI for locally advanced rectal cancer. Clin Colorectal Cancer 17(3):240\u2013246","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"4867_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/DCR.0000000000000752","volume":"60","author":"S Ishihara","year":"2017","unstructured":"Ishihara S, Kawai K, Tanaka T et al (2017) Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. Dis Colon Rectum 60(5):469\u2013476","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"4867_CR13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/DCR.0000000000001866","volume":"64","author":"K Kawai","year":"2021","unstructured":"Kawai K, Shiratori H, Hata K et al (2021) Optimal size criteria for lateral lymph node dissection after neoadjuvant chemoradiotherapy for rectal cancer. Dis Colon Rectum 64(3):274\u2013283","journal-title":"Dis Colon Rectum"},{"key":"4867_CR14","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB, et al. 2017 The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging the: eighth edition AJCC cancer staging manual. CA Cancer J Clin. 67 2 93\u201399","DOI":"10.3322\/caac.21388"},{"key":"4867_CR15","doi-asserted-by":"crossref","unstructured":"Japanese Society for Cancer of the Colon and Rectum. 2019 Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English edition [secondary publication]. J Anus Rectum Colon. 3(4):175\u2013195","DOI":"10.23922\/jarc.2019-018"},{"issue":"28","key":"4867_CR16","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679","journal-title":"Stat Med"},{"issue":"12","key":"4867_CR17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/bjs.10993","volume":"105","author":"R Clifford","year":"2018","unstructured":"Clifford R, Govindarajah N, Parsons JL, Gollins S, West NP, Vimalachandran D (2018) Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. Br J Surg 105(12):1553\u20131572","journal-title":"Br J Surg"},{"issue":"6","key":"4867_CR18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579\u2013588","journal-title":"Lancet Oncol"},{"issue":"8","key":"4867_CR19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C R\u00f6del","year":"2015","unstructured":"R\u00f6del C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16(8):979\u2013989","journal-title":"Lancet Oncol"},{"issue":"18","key":"4867_CR20","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","volume":"32","author":"MJ O\u2019Connell","year":"2014","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32(18):1927\u20131934","journal-title":"J Clin Oncol"},{"key":"4867_CR21","doi-asserted-by":"publisher","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ, et al. 2015 Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III Randomized Clinical Trial. J Natl Cancer Inst. 107(11). https:\/\/doi.org\/10.1093\/jnci\/djv248","DOI":"10.1093\/jnci\/djv248"},{"issue":"20","key":"4867_CR22","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20):2773\u20132780","journal-title":"J Clin Oncol"},{"issue":"10","key":"4867_CR23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol 28(10):1638\u20131644","journal-title":"J Clin Oncol"},{"issue":"4","key":"4867_CR24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bjc.6603570","volume":"96","author":"R Glynne-Jones","year":"2007","unstructured":"Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D (2007) A phase I\/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 96(4):551\u2013558","journal-title":"Br J Cancer"},{"issue":"4","key":"4867_CR25","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ijrobp.2009.12.073","volume":"79","author":"YS Hong","year":"2011","unstructured":"Hong YS, Kim DY, Lim SB et al (2011) Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 79(4):1171\u20131178","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4867_CR26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.29.7697","volume":"29","author":"S Gollins","year":"2011","unstructured":"Gollins S, Sun Myint A, Haylock B et al (2011) Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol 29(8):1042\u20131049","journal-title":"J Clin Oncol"},{"issue":"3","key":"4867_CR27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijrobp.2013.02.020","volume":"86","author":"M Mohiuddin","year":"2013","unstructured":"Mohiuddin M, Paulus R, Mitchell E et al (2013) Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 86(3):523\u2013528","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"4867_CR28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/codi.15905","volume":"24","author":"C Dahlb\u00e4ck","year":"2022","unstructured":"Dahlb\u00e4ck C, Korsbakke K, Alshibiby Bergman T, Zaki J, Zackrisson S, Buchwald P (2022) Accuracy of magnetic resonance imaging staging of tumour and nodal stage in rectal cancer treated by primary surgery: a population-based study. Colorectal Dis 24(9):1047\u20131053","journal-title":"Colorectal Dis"},{"issue":"10","key":"4867_CR29","doi-asserted-by":"crossref","first-page":"e2340256","DOI":"10.1001\/jamanetworkopen.2023.40256","volume":"6","author":"M Diefenhardt","year":"2023","unstructured":"Diefenhardt M, Martin D, Fleischmann M et al (2023) Overall survival after treatment failure among patients with rectal cancer. JAMA Netw Open 6(10):e2340256","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4867_CR30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12885-023-10941-z","volume":"23","author":"S Abe","year":"2023","unstructured":"Abe S, Kawai K, Nozawa H et al (2023) Preoperative chemoradiotherapy using tegafur\/uracil oral leucovorin and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial. BMC Cancer 23(1):450","journal-title":"BMC Cancer"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-04867-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:43:03Z","timestamp":1743280983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-04867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4867"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-04867-0","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"19 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committees of the University of Tokyo (no. 3252-[]).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for their records to be used in the clinical study before receiving treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"76"}}